Risk Factors Update Summary

• The company had 655 full-time and part-time employees as of January 31, 2024, up from 641.
• The company may face fines of up to €20 million or 4% of total worldwide annual turnover for GDPR non-compliance.
• The company received $100.0 million in gross proceeds from a senior secured delayed draw term loan facility in August 2023.
• New regulations like the California Privacy Rights Act and Colorado Privacy Act may significantly impact operations.
• Accumulated deficit increased to $1.2 billion as of December 31, 2023, from $833.9 million.
• Net losses were $557.0 million and $507.0 million for the years ended December 31, 2022 and 2021, respectively.
• Collaboration agreement with Roche for GAVRETO was terminated for convenience in February 2023.
• Failure to meet net sales milestone thresholds under the Royalty Purchase Agreement with Royalty Pharma.
• The company relies on third parties for clinical trials, which may lead to delays or compliance issues.
• The company's dependence on others for drug substance and product, with sole suppliers, poses supply chain risks.